EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Towards New Strategies: Case Report and Review of the Literature—Effective Use of JAK Inhibitor Baricitinib in a 4-Year-Old Boy with Anti-MDA5 Antibody-Positive Juvenile Dermatomyositis

Oana Buzoianu, Özlem Satirer, Jasmin B Kuemmerle-Deschner, Christiane Reiser iD

Journal of Clinical Medicine · 15.01.2026 · 15 (2) · 709

DOI: 10.3390/jcm15020709 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Clinical Medicine, online erschienen am 15.01.2026. Verfasst von Oana Buzoianu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Rheumatology, Department of Pediatrics and Autoinflammation Reference Center Tuebingen, University Hospital Tuebingen, 72076 Tu…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Juvenile dermatomyositis (JDM) is a rare, idiopathic autoimmune disorder characterized by inflammation of both muscle and skin, with a significant contribution from the interferon (IFN) pathway in its pathogenesis. Here, we present the case of a 4-year-old boy with JDM who tested positive for Mi2-α and MDA5 antibodies and showed combined muscle and skin involvement. In view of his markedly elevated IFN signature, the Janus kinase (JAK) inhibitor baricitinib was introduced very early as a targeted steroid-sparing agent in addition to standard immunosuppressive therapy. The patient experienced marked clinical improvement, with resolution of skin lesions, normalization of MDA5 antibodies, and a pronounced reduction in the IFN signature. This case highlights the potential efficacy of JAK inhibition in managing JDM with a high IFN signature and supports a mechanism-based, interferon-targeted treatment approach, in line with emerging evidence in refractory JDM. Further studies are warranted to define the role of JAK inhibitors in the treatment of JDM.

Schlagwörter

Stichwörter der Autor:innen

JAK inhibitorsMDA-5 antibodiesinterferon signaturejuvenile dermatomyositis

Autor:innen und Institutionen

  • Division of Pediatric Rheumatology, Department of Pediatrics and Autoinflammation Reference Center Tuebingen, University Hospital Tuebingen, 72076 Tuebingen, Germany.
  • Department of Pediatrics, Landeskrankenhaus Bregenz, Carl-Pedenz-Str. 2, 6900 Bregenz, Austria.

ORCID-Profile: Christiane Reiser

Zitieren

APA

Buzoianu, O., Satirer, Ö., Kuemmerle-Deschner, J. B., & Reiser, C. (2026). Towards New Strategies: Case Report and Review of the Literature—Effective Use of JAK Inhibitor Baricitinib in a 4-Year-Old Boy with Anti-MDA5 Antibody-Positive Juvenile Dermatomyositis. Journal of Clinical Medicine, 15(2), 709. https://doi.org/10.3390/jcm15020709

Vancouver

Buzoianu O, Satirer Ö, Kuemmerle-Deschner JB, Reiser C. Towards New Strategies: Case Report and Review of the Literature—Effective Use of JAK Inhibitor Baricitinib in a 4-Year-Old Boy with Anti-MDA5 Antibody-Positive Juvenile Dermatomyositis. Journal of Clinical Medicine. 2026;15(2):709. doi:10.3390/jcm15020709

BibTeX
@article{Buzoianu2026,
  author = {Buzoianu, Oana and Satirer, Özlem and Kuemmerle-Deschner, Jasmin B and Reiser, Christiane},
  title = {Towards New Strategies: Case Report and Review of the Literature—Effective Use of JAK Inhibitor Baricitinib in a 4-Year-Old Boy with Anti-MDA5 Antibody-Positive Juvenile Dermatomyositis},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {2},
  pages = {709},
  doi = {10.3390/jcm15020709}
}
Kostenlos starten →